Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Safety and Efficacy of Tivozanib in First-Line mRCC
  2. The Prognosis and Clinicopathologic Features of Different Metastatic Patterns in RCC
  3. High-Dose IL-2 and SAbR for Metastatic Renal Cell Carcinoma
  4. VEGFR-TKIs Plus Immune Checkpoint Inhibitors in Metastatic RCC With Favorable Prognosis
  5. Cabozantinib With Nivolumab and Ipilimumab for Genitourinary Malignancies
  6. Cabozantinib as Immune Modulatory Therapy for Advanced RCC
  7. Alternative Schedule and Dosing of Ipilimumab in RCC
  8. Adjuvant Pembrolizumab vs Placebo for DFS Benefit in RCC
  9. Continuation or Temporary Cessation of First-line Treatment for Advanced RCC
  10. Tumor Burden Is Associated With PFS in mRCC Treated With First-Line Nivo+Ipi

Elsewhere

Recently Updated